Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche , accusing it of " sabotaging competition " by " deliberately " hiking prices in the US , while raising the prices of Avastin , Herceptin , and Rituxan / MabThera in Russia , where Biocad was its selling biosimilar drugs . Amgen won a court ruling saying notice should be provided 180 days before FDA marketing approval can be granted, and Sandoz is asking the US Supreme Court to reverse the decision. The lawsuit , filed recently in New York , claims Roche and its Genentech unit were " engaged in predatory pricing " to prevent Biocad from entering the market . Biologic price was $ 128 m last year , and it is predicted that it could save Europe and the US between $ 50bn and $ 110bn by 2020 .
Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche , accusing it of " sabotaging competition " by " deliberately " hiking prices in the US , while raising the prices of Avastin , Herceptin , and Rituxan / MabThera in Russia , where Biocad was its selling biosimilar drugs . The lawsuit , filed recently in New York , claims Roche and its Genentech unit were " engaged in predatory pricing " to prevent Biocad from entering the market . Biologic price was $ 128 m last year , and it is predicted that it could save Europe and the US between $ 50bn and $ 110bn by 2020 .